Revolutionising Cystic Fibrosis: Unwinding the Complexities for Innovative Therapeutic Insights

Cystic fibrosis (CF) is a life-threatening autosomal recessive disorder caused by mutations in the cystic fibrosistransmembrane conductance regulator (CFTR) gene. These genetic alterations impair chloride and bicarbonate iontransport across epithelial surfaces, resulting in thick, sticky mucus that accumulates in the lungs, pancreas, andother organs. The consequences include recurrent respiratory infections, progressive lung damage, and nutritionaldeficiencies, making CF a complex multisystem disease requiring lifelong management. Recent decades havewitnessed major advancements in CF therapy. The development of CFTR modulators, such as ivacaftor and triplecombinationregimens (elexacaftor/tezacaftor/ivacaftor), has revolutionised care by directly targeting the underlyingmolecular defect rather than just managing symptoms. These therapies have demonstrated improvements in lungfunction, quality of life, and life expectancy, marking a paradigm shift in treatment. In parallel, nanotechnology hasemerged as a powerful tool for drug delivery, enabling nanoparticles to enhance drug stability, improvebioavailability, and deliver therapies more precisely to affected tissues, thereby minimising systemic side effects.Cutting-edge genetic approaches, particularly CRISPR-Cas9–based genome editing, hold promise for correctingCFTR mutations at their source. Although still experimental, these strategies could provide long-term or evencurative solutions. Alongside pharmacological and genetic interventions, epidemiological research and improveddiagnostic techniques are shaping early detection and personalised treatment plans.Keywords: Cystic Fibrosis, CFTR Modulators, Nanotechnology, CRISPR-Cas9, Personalised Medicine